Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Emergent BioSolutions Stock (NYSE: EBS) stock price, news, charts, stock research, profile.
Open3.400 | Close- |
Vol / Avg.559.941K / 2.353M | Mkt Cap166.301M |
Day Range3.220 - 3.405 | 52 Wk Range3.080 - 21.880 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.470 | -1.060 | -0.5900 | ||||
REV | 217.030M | 337.900M | 120.870M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-29 | Benchmark | Robert Wasserman | Downgrades | BuyHold | - | - | - |
2023-05-31 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-05-19 | Benchmark | Robert Wasserman | Reiterates | BuyBuy | Maintains | - | 22.00 |
2023-04-10 | Benchmark | Robert Wasserman | Upgrades | HoldBuy | Announces | - | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
EBS | Emergent BioSolutions | -5.59% | 166.3M |
ORTX | Orchard Therapeutics | 2.2% | 179.5M |
VAXX | Vaxxinity | -5.84% | 163.5M |
CARM | CARISMA Therapeutics | 1.89% | 173.6M |
LRMR | Larimar Therapeutics | -3.42% | 165.1M |
You can purchase shares of Emergent BioSolutions (NYSE: EBS) through any online brokerage.
Other companies in Emergent BioSolutions’s space includes: Orchard Therapeutics (NASDAQ:ORTX), Vaxxinity (NASDAQ:VAXX), CARISMA Therapeutics (NASDAQ:CARM), Larimar Therapeutics (NASDAQ:LRMR) and Fusion Pharmaceuticals (NASDAQ:FUSN).
The latest price target for Emergent BioSolutions (NYSE: EBS) was reported by Benchmark on Tuesday, August 29, 2023. The analyst firm set a price target for 0.00 expecting EBS to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.
The stock price for Emergent BioSolutions (NYSE: EBS) is $3.21 last updated Today at October 2, 2023 at 5:33 PM UTC.
There is no dividend information for Emergent BioSolutions.
Emergent BioSolutions’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Emergent BioSolutions.
Emergent BioSolutions is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.